BRPI0415525A - derivados de imidazola e seu uso como agentes farmacêuticos - Google Patents

derivados de imidazola e seu uso como agentes farmacêuticos

Info

Publication number
BRPI0415525A
BRPI0415525A BRPI0415525-4A BRPI0415525A BRPI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A
Authority
BR
Brazil
Prior art keywords
pharmaceutical agents
imidazole derivatives
cancer
compounds
treatment
Prior art date
Application number
BRPI0415525-4A
Other languages
English (en)
Inventor
Konrad Honold
Stefan Scheiblich
Thomas Von Hirschheydt
Edgar Voss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415525A publication Critical patent/BRPI0415525A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"DERIVADOS DE IMIDAZOLA E SEU USO COMO AGENTES FARMACêUTICOS". Compostos da fórmula geral (I): são produtos terapêuticos valiosos para o tratamento de câncer e doenças relacionadas ao câncer.
BRPI0415525-4A 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos BRPI0415525A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023677 2003-10-17
PCT/EP2004/011598 WO2005040154A1 (en) 2003-10-17 2004-10-15 Novel imidazole derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
BRPI0415525A true BRPI0415525A (pt) 2006-12-26

Family

ID=34486074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415525-4A BRPI0415525A (pt) 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos

Country Status (16)

Country Link
US (1) US7169781B2 (pt)
EP (1) EP1678163B1 (pt)
JP (1) JP2007508344A (pt)
KR (1) KR100796971B1 (pt)
CN (1) CN1867563A (pt)
AR (1) AR046286A1 (pt)
AT (1) ATE420084T1 (pt)
AU (1) AU2004283845A1 (pt)
BR (1) BRPI0415525A (pt)
CA (1) CA2538134A1 (pt)
DE (1) DE602004018962D1 (pt)
ES (1) ES2317030T3 (pt)
MX (1) MXPA06003698A (pt)
RU (1) RU2006116628A (pt)
TW (1) TW200528447A (pt)
WO (1) WO2005040154A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1889836E (pt) 2005-08-24 2013-08-28 Eisai R&D Man Co Ltd Novo derivado de piridina e derivado de pirimidina (3)
ATE453635T1 (de) * 2006-03-22 2010-01-15 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
AU2007261440A1 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
ES2375284T3 (es) 2006-08-23 2012-02-28 Eisai R&D Management Co., Ltd. Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma.
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
ES2689444T3 (es) 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
MX2009011810A (es) * 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) * 2007-05-24 2010-02-04 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2010003563A (es) * 2007-10-03 2010-06-02 Vertex Pharma Inhibidores de proteina cinasa de c-met.
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
BR112012019302B1 (pt) 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CA2892045C (en) 2012-11-21 2022-05-31 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
NZ748260A (en) 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
WO1996018626A1 (en) 1994-12-13 1996-06-20 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
EP0994870A4 (en) 1997-06-19 2002-10-23 Smithkline Beecham NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles

Also Published As

Publication number Publication date
ES2317030T3 (es) 2009-04-16
TW200528447A (en) 2005-09-01
ATE420084T1 (de) 2009-01-15
KR20060063985A (ko) 2006-06-12
AR046286A1 (es) 2005-11-30
MXPA06003698A (es) 2006-06-05
WO2005040154A1 (en) 2005-05-06
JP2007508344A (ja) 2007-04-05
CN1867563A (zh) 2006-11-22
KR100796971B1 (ko) 2008-01-22
US20050113342A1 (en) 2005-05-26
EP1678163A1 (en) 2006-07-12
CA2538134A1 (en) 2005-05-06
RU2006116628A (ru) 2007-11-27
DE602004018962D1 (de) 2009-02-26
AU2004283845A1 (en) 2005-05-06
EP1678163B1 (en) 2009-01-07
US7169781B2 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
GB0022438D0 (en) Organic Compounds
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
SE0301700D0 (sv) Novel compounds
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
DE50310516D1 (de) Fredericamycin-derivate
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
TW200505452A (en) Chemical compounds
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BRPI0416674A (pt) tiazolidinona amidas, amidas de ácido tiazolidino carboxìlico, processos de fabricação, e uso das mesmas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.